Soluble CD25 as a predictor of hepatocellular carcinoma compared with alpha-fetoprotein

Shaymaa Nafady Abdelfattah1, Alaa Farouk Haseeb1, Mohammad Mohammad Tawfik1, Doaa Mahmoud Khalil2, Dina Attia1

1Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
2Public Health and Community Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt

Abstract

Aim of the study: We aimed to evaluate soluble CD25 (sCD25) as a marker for hepatocellular carcinoma (HCC) diagnosis.

Material and methods: Eighty-eight subjects were enrolled in our study in the years 2017-2018. They were divided into three groups as follows: group 1 – HCC group (n = 44) patients, represented by BCLC stage A (n = 16) patients, stage B (n = 14) patients and stage C (n = 14) patients for each stage. All HCC patients were on top of cirrhosis. Group 2 – group of cirrhotic patients without HCC (n = 32); 50% of them were Child-Turcotte-Pugh class A (n = 16) while class B was represented only by 43.7% (n = 14) of patients. Group 3 – control group (n = 12) of healthy subjects.

Results: The levels of sCD25 and AFP were higher in HCC patients than cirrhotic and control groups without a statistically significant difference between the three groups (p-value > 0.05). For HCC presence, sensitivity and specificity of sCD25 were 86.4% and 29.5% respectively at a cut-off value of 1.1 × 10³ pg/ml (AUC = 0.619, p-value = 0.054, PPV = 33.2%, NPV = 68.44%). For early detection of HCC, sCD25 had a sensitivity of 70.5% and a specificity of 30.9% at a cut-off value of 1.575 × 10³ pg/ml (AUC = 0.577, p-value = 0.251, PPV = 58.5%, NPV = 43.1%), while the sensitivity and specificity of AFP were 75% and 62.5% respectively at a cut-off value of 9.5 ng/ml (AUC = 0.828, p = 0.000, PPV = 73.4%, NPV = 64.4%) in the same settings.

Conclusions: sCD25 seems to offer no better detection rate of HCC compared to AFP with lower sensitivity and specificity.

Key words: hepatocellular carcinoma, alpha-fetoprotein, HCC markers, soluble CD25.

Address for correspondence

Dr. Shaymaa Nafady Abdelfattah, Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, e-mail: shnafady@yahoo.com

Introduction

Hepatocellular carcinoma (HCC) is reported as the most frequently detected primary liver malignancy [1]. It is the 5th most common cancer in males and the 9th most common in females worldwide [2]. There is a high prevalence of both hepatitis C virus (HCV) and hepatitis B virus (HBV) infections in Egypt, which resulted in an increasing HCC incidence rate in the past ten years [3]. HCC has many risk factors. In most cases, it occurs as a complication of chronic liver disease. The most important disease leading to HCC is liver cirrhosis.

Early HCC detection is the key for improving outcome. Currently, we use α-fetoprotein (AFP) and abdominal ultrasound for screening. AFP has been used for HCC diagnosis historically [4]. At levels more than 400 ng/ml, it is considered to be diagnostic [5]. However, many studies have shown unreliable AFP sensitivity and specificity. So HCC diagnosis depends on radiological characteristics and histology [6], which highlights the importance of developing new markers.

The immune system plays an important role in inhibition of cancer proliferation. However, cancer can manipulate the immune system mechanisms and overcome them [7]. The liver microenvironment has
a unique immune response regarding HCC metastasis [8]. Lymphocytes play a very important role by way of inflammation and immunity. HCC develops on top of chronic inflammation where lymphocytes are a major component of this inflammatory microenvironment [9]. They interact with other innate immune cells directly or through chemokines and cytokines, e.g. interferon γ (IFN-γ) affecting tumor growth [10]. Both T and B lymphocytes infiltrate HCC, interfering with its proliferation and interacting with each other again through chemokines and cytokines [11] with better survival [12]. Although there is substantial lymphocytic infiltration, a tumor can progress [13]. This indicates that there is either inactivation of anti-tumor effector T cells or immune tolerance induction.

Soluble CD25 is involved in the immune response to many tumors including HCC. It is a protein that is encoded by the IL-2RA gene in humans [14]. It binds competitively to IL-2R, inhibiting lymphocyte proliferation and down-regulating NK activity. This interferes with the immune system function, making the level of sCD25 an indicator of immune system inhibition [15]. Cabrena et al. [16] found that HCC patients have significantly higher levels of sCD25 compared to control with a significant positive correlation between its level and tumor stage.

Material and methods

Studied subjects

Eighty-eight subjects were enrolled in our study. They were recruited from Beni-Suef University Hospital, Egypt in the years 2017-2018. This study was approved by the Research Ethical Committee of Beni-Suef University and all individuals provided written informed consent prior to participation in any procedure. They were divided into three groups as follows: group 1, HCC group (n = 44) patients, represented by BCLC stage A (n = 16) patients, stage B (n = 14) patients and stage C (n = 14) patients for each stage. In all HCC patients it was on top of cirrhosis; group 2, cirrhotic group without HCC (n = 32) patients; 50% of them were Child-Turcotte-Pugh class A (n = 16) while class B was represented only by 43.7% (n = 14) patients; 50% of all HCC patients it was on top of cirrhosis; group 3, healthy group (n = 14) patients included in the study. Regarding Child-Pugh classification, class B represented 47.7% of HCC patients and 43.8% of the cirrhotic group while class A represented 50% of the cirrhotic group and 40.9% of HCC group. There was no statistically significant difference between the groups (p-value = 0.628).

The serum levels of both sCD25 and AFP were detected at a higher level in the HCC patients than cirrhotic and control groups. There was no a statistically significant difference (p-value > 0.05) between different
groups for both markers. The levels of both markers in different studied groups are summarized in Table 2.

We compared between different tumor size (less than 2 cm, 2-5 cm and more than 5 cm) groups regarding serum levels of sCD25 and AFP. There was no statistically significant difference between mean sCD25 or AFP and different tumor size categories ($p$-value > 0.05) (Table 3).

This analysis showed that at a cut-off value of $1.1 \times 10^3$ pg/ml, sCD25 had a sensitivity of 86.4% and a specificity of 29.5% for detecting HCC and the area under the curve (AUC) value was 0.619 ($p = 0.054$). The positive predictive value (PPV) was 33.2% while the negative predictive value (NPV) was 68.44%. By comparison, AFP had a sensitivity of 65.9% and a specificity of 99.1% at a cut-off value of 30.8 ng/ml (AUC = 0.860, $p = 0.000$, PPV = 98.7%, NPV = 74.3%) (Fig. 1). We investigated the role of sCD25 in detecting early HCC (stage A). We compared the level of sCD25 in patients with BCLC stage A HCC with the sCD25 responses of cirrhotic patients. In ROC analysis, an optimal cut-off value of $1.575 \times 10^3$ pg/ml for sCD25 had a sensitivity of 70.5% and a specificity of 30.9% (AUC = 0.577, $p = 0.251$, PPV = 25.6%, NPV = 57.1%) (Fig. 2).

Table 1. Comparison between hepatocellular carcinoma, cirrhotic and control groups regarding baseline characteristics

| Characteristics | Group     | N   | Mean ±SD       | $p$-value | 95% CI for mean | Range   |
|-----------------|-----------|-----|----------------|-----------|-----------------|---------|
| WBCs ($\times 10^3$/dl) | HCC       | 44  | 6.6 ±4.02      | 0.656     | 5.4 7.8         | 2.23    |
|                 | Cirrhotic | 32  | 6.7 ±3.5       |           | 5.4 7.9         | 2.5-19  |
|                 | Control   | 12  | 5.6 ±1.4       |           | 4.7 6.5         | 3.5-8   |
| HB (g/dl)       | HCC       | 44  | 11.04 ±1.9     | 0.001     | 10.5 11.6       | 7.5-14.3|
|                 | Cirrhotic | 32  | 9.9 ±1.5       |           | 9.5 10.5        | 7.12    |
|                 | Control   | 12  | 11.9 ±1.3      |           | 11.2 12.8       | 9.9-14  |
| PLT ($\times 10^3$/dl) | HCC       | 44  | 137.5 ±56.9    | < 0.001   | 120.2 154.8     | 21-320  |
|                  | Cirrhotic | 12  | 115.7 ±57.2    |           | 95.1 136.3      | 9.8-325 |
|                  | Control   | 12  | 260.3 ±75.7    |           | 212.1 308.3     | 166-400 |
| Albumin (g/dl)  | HCC       | 44  | 3.1 ±0.6       | < 0.001   | 2.9 3.2         | 2.5     |
|                  | Cirrhotic | 32  | 2.6 ±0.7       |           | 2.4 2.9         | 1.2-3.9 |
|                  | Control   | 12  | 4.1 ±0.4       |           | 3.8 4.3         | 3.5-5   |
| INR             | HCC       | 44  | 1.4 ±0.3       | 0.005     | 1.3 1.5         | 1-2.2   |
|                 | Cirrhotic | 32  | 1.6 ±0.7       |           | 1.3 1.9         | 1-4.3   |
|                 | Control   | 12  | 1.1 ±0.1       |           | 0.9 1.1         | 1-1.3   |
| Creatinine (mg/dl) | HCC       | 44  | 1.4 ±1.03      | 0.094     | 1.1 1.7         | 0.5-5.9 |
|                  | Cirrhotic | 32  | 1.1 ±0.5       |           | 0.9 1.3         | 0.5-2.8 |
|                  | Control   | 12  | 0.8 ±0.3       |           | 0.7 1           | 0.5-1.3 |
| BIL (mg/dl)     | HCC       | 44  | 3.5 ±5.7       | 0.084     | 1.7 5.2         | 0.5-30  |
|                  | Cirrhotic | 32  | 1.7 ±1.6       |           | 1.1 2.4         | 0.5-10.25|
|                  | Control   | 12  | 0.9 ±0.3       |           | 0.6 1.1         | 0.3-1.25|
| AST (U/ml)      | HCC       | 44  | 83.8 ±64.3     | 0.001     | 64.3 103.4      | 16-346  |
|                  | Cirrhotic | 32  | 64.2 ±32.9     |           | 52.3 76.1       | 26-169  |
|                  | Control   | 12  | 20.8 ±7.5      |           | 16.1 25.6       | 10-33   |
| ALT (U/ml)      | HCC       | 44  | 66.9 ±59.1     | < 0.001   | 48.9 84.9       | 12-264  |
|                  | Cirrhotic | 32  | 34 ±14.1       |           | 28.9 39.1       | 11-64   |
|                  | Control   | 12  | 20.8 ±7.1      |           | 16.3 25.3       | 10-31   |

SD – standard deviation, WBCs – white blood cells, HCC – hepatocellular carcinoma, HB – hemoglobin, PLT – platelets, INR – international normalized ratio, BIL – bilirubin, AST – aspartate aminotransferase, ALT – alanine transaminase
Table 2. Comparison between hepatocellular carcinoma, cirrhotic and control groups regarding sCD25 and AFP tumor markers

| Tumor markers | Group    | N   | Mean ±SD       | p-value | Range          |
|---------------|----------|-----|----------------|---------|----------------|
| sCD25 (pg/ml) | HCC      | 44  | 2752 ±1684     | 0.098   | 525.2-7142     |
|               | Cirrhotic | 32  | 2325 ±1542     |         | 438.4-7010     |
|               | Control  | 12  | 1631 ±1595     |         | 107.2-6071     |
| AFP (ng/ml)   | HCC      | 44  | 10814 ±6403    | 0.574   | 2.5-447575     |
|               | Cirrhotic | 32  | 8.9 ±7.3       |         | 1.5-30         |
|               | Control  | 12  | 3.1 ±1.9       |         | 1.7            |

SD – standard deviation, sCD25 – soluble CD25, HCC – hepatocellular carcinoma, AFP – α-fetoprotein.

Table 3. Comparison between different tumor sizes (less than 2 cm, 2-5 cm and more than 5 cm) groups regarding sCD25 and AFP tumor markers

| Marker      | Tumor size (cm) | N   | Mean   | Standard deviation | p-value |
|-------------|-----------------|-----|--------|--------------------|---------|
| sCD25 (pg/ml) | < 2             | 8   | 1952   | 997.2              | 0.195   |
|             | 2-5             | 24  | 2722   | 1553               |         |
|             | > 5             | 12  | 3344   | 2134               |         |
|             | Total           | 44  | 2752   | 1684               |         |
| AFP (ng/ml)  | < 2             | 8   | 163.3  | 163                | 0.284   |
|             | 2-5             | 24  | 1095   | 2593               |         |
|             | > 5             | 12  | 37354  | 129186             |         |
|             | Total           | 44  | 10814  | 67403              |         |

sCD25 – soluble CD25, AFP – α-fetoprotein, N – number.

Table 4. Comparison between different tumor sizes (less than 2 cm, 2-5 cm and more than 5 cm) groups regarding sCD25 and AFP tumor markers

| Marker  | Cut-off | AUC | Standard error | p-value | Asymptotic 95% CI | Sens. % | Spec. % | PPV % | NPV % |
|---------|---------|-----|----------------|---------|--------------------|---------|---------|-------|-------|
| sCD25 (pg/ml) | 1.1 × 10³ | 0.619 | 0.060 | 0.054 | 0.502 | 0.737 | 86.4 | 29.5 | 33.2 | 68.44 |
| AFP (ng/ml) | 30.8 | 0.860 | 0.040 | < 0.001* | 0.781 | 0.938 | 65.9 | 99.1 | 98.7 | 74.3 |

AUC – area under the curve. Sens. – sensitivity, Spec. – specificity, PPV – positive predictive value, NPV – negative predictive value, sCD25 – soluble CD25, AFP – α-fetoprotein.

Fig. 1. Receiver operator characteristic (ROC) curve illustrates the potential of soluble CD25 (sCD25) and α-fetoprotein (AFP) as predictors of hepatocellular carcinoma (HCC).
We tried to study the correlation between both markers and tumor stage or size. There was no statistically significant correlation between both markers and tumor stage (Table 4). We also did not find any statistically significant correlation between them and tumor size (Table 5).

**Discussion**

Hepatocellular carcinoma is a tumor whose early detection has a very good impact on its prognosis and patient survival. So it is important to search for new markers other than AFP with a better sensitivity and specificity for early detection. In our study, the mean age of the studied individuals was 54.9 ±5.8 years in the HCC group. This is in agreement with the study by Mohamed et al. [20], who reported that the most frequent age category affected by HCC was between 51 and 60 years (45.7%). Chronic HCV infection was the underlying cause of liver cirrhosis in all patients included in the study. This is due to high prevalence of HCV in Egypt, and this is in agreement with Mohamed et al. [20]. The serum levels of sCD25 were detected at a higher level in HCC patients than cirrhotic and con-

### Table 4. Correlation between tumor markers (sCD25 and AFP) and tumor stage

| Tumor markers | Tumor stage | Correlation coefficient | Sig. (2-tailed) | Number |
|---------------|-------------|-------------------------|-----------------|--------|
| sCD25         | Correlation coefficient | 0.260                   | 0.088           | 44     |
|               | Sig. (2-tailed)           |                         |                 |        |
| AFP           | Correlation coefficient | 0.084                   | 0.588           | 44     |
|               | Sig. (2-tailed)           |                         |                 |        |

AUC = area under the curve, Sens. = sensitivity, Spec. = specificity, PPV = positive predictive value, NPV = negative predictive value, sCD25 = soluble CD25, AFP = α-fetoprotein

### Table 5. Correlation between tumor markers (sCD25 and AFP) and tumor size

| Tumor markers | Tumor size | Correlation coefficient | Sig. (2-tailed) | Number |
|---------------|------------|-------------------------|-----------------|--------|
| sCD25         | Correlation coefficient | 0.223                   | 0.145           | 44     |
|               | Sig. (2-tailed)           |                         |                 |        |
| AFP           | Correlation coefficient | -0.060                  | 0.700           | 44     |
|               | Sig. (2-tailed)           |                         |                 |        |

sCD25 = soluble CD2, AFP = α-fetoprotein
trol groups. The mean sCD25 level was 2752 ±1684, 2325 ±1542, 1631 ±1595 pg/ml in HCC, cirrhotic and control respectively ($p < 0.098$). AFP level also was higher in HCC patients than the other two groups, also without a statistically significant difference ($p = 0.574$). In comparison with a study conducted by Cabrena et al. [16], they found that levels of sCD25 in HCC patients were significantly higher than those in normal and disease control groups ($p < 0.0001$). Rizk et al. [21] also found the same as Cabrena et al. [16] as sCD25 levels were significantly higher in HCC versus cirrhotic and control groups. Sameea et al. [22] also found in a similar study that serum sCD25 level was significantly higher in HCC patients than cirrhotic patients ($p < 0.0001$) and healthy controls ($p = 0.013$).

We found that at a cut-off value of 1.1 × 10³ pg/ml, sCD25 had a sensitivity of 86.4% and a specificity of 29.5% for detecting HCC (AUC = 0.619, $p = 0.054$, PPV = 33.2%, NPV = 68.44%). By comparison, AFP had a lower sensitivity (65.9%) and a higher specificity (99.1%) at a cut-off value of 30.8 ng/ml (AUC = 0.860, $p < 0.001$, PPV = 98.7%, NPV = 74.3%). Cabrena et al. [16] found that sCD25 had a sensitivity of 92.3% and specificity of 37.7% at a cut-off value of 2,180 pg/ml for the presence of HCC (AUC = 0.685), and when they compared sCD25 with AFP, they found that sCD25 had a higher sensitivity (92.3%) than AFP (53.8%) in detecting the presence of HCC. Rizk et al. [21] found that by using a cut-off value of 1425 pg/ml, sCD25 had a lower sensitivity (64%) and a higher specificity (96.15%) for the presence of HCC than AFP (AUC = 0.7959), while Sameea et al. [22] found a sensitivity of (90%) and a specificity of (84.2%) at a cut-off value of 7 ng/ml for sCD25 (AUC = 0.969, $p < 0.0001$).

We evaluated the performance of sCD25 in detecting early HCC (stage A). sCD25 had both lower sensitivity and lower specificity than AFP regarding early detection of HCC. By comparing the levels of sCD25 in both cirrhotic patients and BCLC (stage A) HCC patients, an optimal cut-off value of 1.575 × 10³ pg/ml for sCD25 had a sensitivity of 70.5% and a specificity of 30.9% (AUC = 0.577, $p = 0.251$, PPV = 58.5%, NPV = 43.1%). By comparison, at a cut-off value of 9.5 ng/ml, AFP had a sensitivity of 75% and a specificity of 62.5% (AUC = 0.828, $p = 0.000$, PPV = 73.4%, NPV = 64.4%). Cabrena et al. [16] found that sCD25 had a higher sensitivity while AFP had a higher specificity for early HCC detection. A cut-off value of 2,859 pg/ml sCD25 had a sensitivity of 89.6% and a specificity of 39.3% (AUC = 0.630, $p < 0.0001$), while Sameea et al. [22] found that the optimal sCD25 cut-off level was 7.15 ng/ml with sensitivity and specificity of 90% and 60% respectively (AUC = 0.717, $p = 0.019$).

When we evaluated the correlation between both markers (sCD25 and AFP) and tumor stage, we did not find any statistically significant correlation ($r$) between both markers and tumor stage ($r$ for sCD25 = 0.260, AFP = 0.084). This result conflicts with that of Cabrena et al. [16], who found a significant positive correlation between tumor stage and sCD25 levels ($R = 0.213$, $p < 0.0160$). They also found a significant positive correlation between serum AFP levels and tumor stage ($R = 0.513$, $p < 0.0001$). We also studied the correlation between both markers and tumor size. Again we found no significant correlation between tumor size and either sCD25 or AFP ($r$ for sCD25 = 0.223, AFP = −0.060).

We could not find an explanation for these conflicting results or for the great variations in cut-off levels. There was a difference between their study and ours in the sample size and the underlying risk factors. There was also dissimilarity in ethnic and racial factors. Other important factors are genetic and environmental background. It is important to note that the underlying etiology of liver disease in our study was only HCV infection. In the study of Cabrena et al. [16], the HCC group had 60% HCV, 13% cryptogenic, 9% non-alcoholic fatty liver disease (NAFLD) and 9% alcoholic cirrhosis as the underlying etiology while the cirrhosis group had 72% HCV, 5% alcoholic cirrhosis, and 5% NAFLD, while 3% were cryptogenic. It is also important to highlight that GT-4 (and subtype 4a in particular) dominates the HCV epidemic in Egypt [23]. We admit that our study had some limitations such as being monocentric with a small number of subjects included in the study. We also had heterogeneous groups of patients regarding Child-Pugh classification, tumor size and BCLC stages.

**Conclusions**

sCD25 seems to offer no better detection rate of HCC compared to AFP, with lower sensitivity and specificity, especially at early stage HCC.

**Disclosure**

Authors report no conflict of interest.

**References**

1. Stuver S, Trichopoulos D. Cancer of the liver and biliary tract. In: Textbook of cancer epidemiology. Adami HO, Hunter D, Trichopoulos D (eds.). 2nd ed. Oxford University Press, Oxford, UK 2008; 308-332.
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2013; 136: E359-E386.
3. El-Garem H, Hafez HA, Foaad A, et al. Tissue biomarkers in the early detection of hepatocellular carcinoma among Egyptian patients with chronic hepatitis C: a possible genetic profile. Br J Med Med Res 2013; 3: 1858-1870.

4. Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.

5. Waller LP, Deshpande V, Pyrsopoulos N. Hepatocellular carcinoma: A comprehensive review. World J Hepatol 2015; 7: 2648-2663.

6. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.

7. Nakamoto Y, Guidotti LG, Kuhlen CV, et al. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-350.

8. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 2-99.

9. Mossanen JC, Tacke F. Role of lymphocytes in liver cancer. Oncoimmunology 2013; 2: e26468.

10. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.

11. Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144: 512-527.

12. Schneider C, Teufel A, Yevsa T, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012; 61: 1733-1743.

13. Harlin H, Kuna TV, Peterson AC, et al. Tumor progression despite massive influx of activated CD8 (+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother 2006; 55: 1185-1197.

14. Leonard WJ, Donlon TA, Lebo RV, et al. Localization of the gene encoding the human interleukin-2 receptor on chromosome 10. Science 1985; 4707: 1547-1549.

15. Goto H, Tsurumi H, Takemura M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: In combination with the International Prognostic Index. J Cancer Res Clin Oncol 2005; 131: 73-79.

16. Cabrena R, Fitian A, Ararat M, et al. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncol Lett 2012; 4: 840-846.

17. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.

18. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649.

19. Oken MM, Creech RH, Torney DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.

20. Shaker MK, Abdella HM, Khalifa MO, et al. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int 2013; 33: 1601-1606.

21. Rizk E, Zakaria S, Abdel-Razik A, et al. Serum soluble CD25 and hepatocellular carcinoma. IJAR 2015; 3: 658-664.

22. Sameea AE, Zakareya T, Metwaly K, et al. Serum soluble CD25 in hepatocellular carcinoma, shall we able to change the natural history? IJMRR 2017; 3: 10-15.

23. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87.